According to the 2021 WHO Classification, the highest number of patients with IDH1 mutation in plasma was found in the astrocytoma G II (40%), and G III (30%), oligodendroglioma (20%), astrocytoma G IV (10%) (Table 2). Here, IDH1 is linked to astrocytoma (excluding glioblastoma).